in vitro News and Research

RSS

New fully human monoclonal antibodies to battle Chikungunya

The Singapore Immunology Network (SIgN), an institute of the Agency of Science, Technology and Research (A*STAR), and VIVALIS, a French biopharmaceutical company, announced today the discovery of two new fully human monoclonal antibodies which could battle Chikungunya, a disease that currently has no available vaccine or specific treatment.

16 Feb 2011

Scientists suggest combinational therapy can improve treatment of solid tumors

Most, if not all, solid tumors contain regions that are not well oxygenated. Tumor cells in these regions, which are known as hypoxic regions, are usually resistant to the death-inducing effects of chemotherapeutics. But now, Caroline Dive and colleagues, at Manchester University, United Kingdom, have identified a compound that induces human cancer cells exposed to hypoxic conditions in vitro to undergo a form of cell death known as apoptosis.

15 Feb 2011

Scientists find molecular pathway that offers novel targets for diabetes therapies

Once people develop type 2 diabetes, high blood glucose levels alter their metabolism so much that it becomes difficult to sift through all the clues to find what might enable the disease.

15 Feb 2011

PsychoGenics establishes alliance with KineMed to provide specialized neurogenesis services

PsychoGenics today announced the establishment of an alliance with KineMed, to provide specialized neurogenesis services to complement PsychoGenics' in vivo testing capabilities.

15 Feb 2011

Public-sector research has had an immediate effect on improving public health: Study

AUTM President Ashley Stevens, D. Phil. (Oxon), CLP is the lead author of The Role of Public Sector Research in the Discovery of Drugs and Vaccines, a paper published in the Feb. 10 issue of The New England Journal of Medicine.

14 Feb 2011

Scientists develop novel treatment strategy for multiple myeloma

Scientists at Virginia Commonwealth University Massey Cancer Center have developed a novel treatment strategy for multiple myeloma that pairs two targeted agents to kill cancer cells. The study's findings, published in today's edition of the journal "Blood," are the first to demonstrate the synergistic, anti-myeloma effects of this combination regimen both in vitro and in vivo.

11 Feb 2011

Medivir initiates phase 1a clinical trial of TMC649128 for chronic HCV infection

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces the start of a phase 1a clinical trial with TMC649128 intended for the treatment of chronic hepatitis C virus infection.

10 Feb 2011

Akonni signs license agreement with USAMRIID to develop multiplex testing products for bio-security applications

Akonni Biosystems, a molecular diagnostics (MDx) company that develops rapid, low-cost and highly scalable solutions for infectious disease testing, today announced it has signed a license agreement with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

10 Feb 2011

Scientists discover KCNH2 gene mutation in patients with long QT syndrome

Researchers from the Hospital Virgen de las Nieves of the University of Granada have identified the most frequent mutations in the gene KCNH2 in patients with long QT syndrome.

10 Feb 2011

Protein cross-linking enzymes in foods can affect physiological characteristics

Protein modification via enzymatic cross-linking is an attractive way for altering food structure so as to create products with increased quality and nutritional value. These modifications are expected to affect not only the structure and physico-chemical properties of proteins but also their physiological characteristics, such as digestibility in the GI-tract and allergenicity.

10 Feb 2011

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

CeNeRx BioPharma, Inc., a clinical-stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced FDA approval of its IND and reported the first clinical results in humans for CXB909, a novel agent that has demonstrated utility in preclinical models of neuroprotection and neurodegenerative disorders.

9 Feb 2011

Gates Foundation awards USF $5.45M for malaria research

The University of South Florida received $5.45 million in grants from the Bill & Melinda Gates Foundation. The first grant is to create advanced devices that mimic the human liver to better study the life cycle of the malaria parasite - particularly the elusive liver stage where the disease may be most vulnerable to attack.

9 Feb 2011

Tufts announces public launch of Institute for Biomedical Partnerships, HUB website

Tufts University today announced the public launch of the Tufts Institute for Biomedical Partnerships website/HUB: www.tuftspharmapartners.org.

8 Feb 2011

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

PharmaMar SA has announced the commencement of a Phase I clinical trial with PM060184 for patients with solid tumors. PM060184 is a marine-derived, synthetically-produced compound which has shown strong in vitro and in vivo antitumor activity and a favorable safety profile in preclinical toxicology studies. PM060184 is PharmaMar's sixth compound in clinical development.

7 Feb 2011

AMRI fourth quarter total revenue increases 12% to $48.6 million

AMRI today reported financial and operating results for the fourth quarter and full year ended December 31, 2010.

7 Feb 2011

Roche launches cobas TaqScreen DPX Test for parvovirus B19 and hepatitis A virus

Roche announced today that the cobas® TaqScreen DPX Test for use on the cobas s 201 system is now available in the US. It is the first commercial test to quantify parvovirus B19 and detect hepatitis A virus (HAV) simultaneously in one assay in human plasma.

5 Feb 2011

Cholesterol efflux capacity may protect against heart disease: Study

The discovery that high levels of high-density lipoprotein cholesterol are associated with reduced risk of cardiovascular disease has fostered intensive research to modify HDL levels for therapeutic gain. However, recent findings have called into question the notion that pharmacologic increases in HDL cholesterol levels are necessarily beneficial to patients.

4 Feb 2011

Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI

Concert Pharmaceuticals, Inc. today announced that it has entered into a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Research. The CRADA will allow the WRAIR to conduct preclinical testing on a novel compound derived from Concert's DCE Platform™ (deuterated chemical entity platform) for seizure protection associated with traumatic brain injury, a major public health concern.

3 Feb 2011

Uterine health is more relevant for fetus to achieve normal birth weight, full gestation

For women seeking pregnancy by assisted reproductive technologies, such as in-vitro fertilization, a new study shows that the health of the uterus is more relevant than egg quality for a newborn to achieve normal birth weight and full gestation.

2 Feb 2011

PET imaging may play a role in early evaluation of vandetanib response in thyroid cancer

Positron emission tomography can image metabolic changes following treatment with the protein kinase inhibitor vandetanib, helping to define the therapy response or the effectiveness of the therapeutic agent, according to research published in the February issue of The Journal of Nuclear Medicine.

1 Feb 2011

in vitro News and Research

New fully human monoclonal antibodies to battle Chikungunya

Scientists suggest combinational therapy can improve treatment of solid tumors

Scientists find molecular pathway that offers novel targets for diabetes therapies

PsychoGenics establishes alliance with KineMed to provide specialized neurogenesis services

Public-sector research has had an immediate effect on improving public health: Study

Scientists develop novel treatment strategy for multiple myeloma

Medivir initiates phase 1a clinical trial of TMC649128 for chronic HCV infection

Akonni signs license agreement with USAMRIID to develop multiplex testing products for bio-security applications

Scientists discover KCNH2 gene mutation in patients with long QT syndrome

Protein cross-linking enzymes in foods can affect physiological characteristics

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

Gates Foundation awards USF $5.45M for malaria research

Tufts announces public launch of Institute for Biomedical Partnerships, HUB website

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

AMRI fourth quarter total revenue increases 12% to $48.6 million

Roche launches cobas TaqScreen DPX Test for parvovirus B19 and hepatitis A virus

Cholesterol efflux capacity may protect against heart disease: Study

Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI

Uterine health is more relevant for fetus to achieve normal birth weight, full gestation

PET imaging may play a role in early evaluation of vandetanib response in thyroid cancer

eBook: Using iPSCs models for human disease research and drug discovery eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News